ArticleCardiovascular toxicology2025
Serum Copper and Heart Failure: A Cross-Sectional and In Silico Toxicological Study.
Article in Cardiovascular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Heart failure (HF) is a major public health concern marked by substantial morbidity and mortality. Emerging evidences suggest that copper (Cu) may be implicated in cardiovascular diseases, but its relationship with HF remains inadequately understood. This study was conducted to investigate the association between serum copper levels and the prevalence of HF, while exploring potential underlying mechanisms using network toxicology. Data were derived from 5139 participants aged 18-80 years in the NHANES 2011-2016 cycle. Serum copper levels were measured using inductively coupled plasma dynamic reaction cell mass spectrometry (ICP-DRC-MS). Logistic regression and restricted cubic spline models were employed to evaluate the association between serum copper and HF. A network toxicology approach, incorporating database mining (CTD and ChEMBL), protein-protein interaction (PPI) network analysis, Gene Ontology (GO), and KEGG pathway enrichment, was utilized to elucidate potential molecular mechanisms. Elevated serum copper levels were significantly associated with increased prevalence of HF (OR 1.08, 95% CI 1.03-1.13; p = 0.0008). A significant sex-based interaction was observed, with a stronger association evident among males. Through in silico analysis, a total of 108 copper-related HF target genes were identified, with TP53, IL-1B, IL-6, TNF, AKT1, and ALB recognized as hub genes. Enriched KEGG pathways included lipid metabolism and atherosclerosis, apoptosis, MAPK signaling, ROS-mediated chemical carcinogenesis, and AGE-RAGE signaling in diabetic complications. Mechanistically, copper-induced oxidative stress, apoptosis, and immune dysregulation were implicated in HF pathogenesis. Serum copper levels demonstrate an independent association with HF prevalence. However, due to the cross-sectional design of the study, causal inference cannot be established. Network toxicological analysis highlights key biological pathways such as oxidative stress and apoptosis, offering mechanistic insights into the role of copper in HF development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.